Show notes
In this episode of Derms and Conditions, Dr James Q. Del Rosso welcomes back hislongtime friend and pediatric dermatology expert, Dr Lisa Swanson. Together, theyexplore the rapidly evolving treatment landscape for pediatric atopic dermatitis, with afocus on newly approved non-steroidal topical therapies.Dr Swanson shares her insights on tapinarof 1% cream, now FDA-approved for patientsas young as two years old, and topical roflumilast 0.15% cream, approved down to agesix. The duo discusses how aryl hydrocarbon receptor (AhR) agonism makes tapinarofeffective in both atopic dermatitis and psoriasis, likening its action to a “SNOO” thatadjusts to soothe inflammation.They also dive into data from the ADORING 1 and ADORING 2 phase 3 trials,highlighting tapinarof’s rapid reduction in itch and its positive impact on sleep—criticaloutcomes for both children and their parents. Dr Swanson offers real-world anecdotesabout the sleep-depriving toll of pediatric eczema and how effective therapies canrestore rest for the entire family.The conversation touches on skin of color considerations, including how atopicdermatitis may present differently and why diverse representation in clinical trials isessential. Dr Swanson underscores the importance of tactile assessments and sharespractical pearls for evaluating eczema severity across skin types.Finally, they explore safety and tolerability, emphasizing tapinarof’s low risk of systemicabsorption, even in young children prone to thumb-sucking or hand-to-mouth behavior.Tune in for clinical pearls, new treatment insights, and a few laughs between twodermatology BFFs.



